

This article was downloaded by:

On: 29 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Phosphorus, Sulfur, and Silicon and the Related Elements

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713618290>

Bisphosphonates. VI. Methylenebisphosphonic Acid Partial Esters and Amides

E. Pohjala^{ab}; H. Nupponen^{ab}; J. Vepsäläinen^{cd}; H. Nikander^{bc}; M. L. Heikkilä-Hoikka^{bc}

^a University of Kuopio, Tampere ^b University of Kuopio, Leiras Oy ^c University of Kuopio, Turku, Finland ^d University of Kuopio, Kuopio, Finland

To cite this Article Pohjala, E. , Nupponen, H. , Vepsäläinen, J. , Nikander, H. and Heikkilä-Hoikka, M. L.(1993)
'Bisphosphonates. VI. Methylenebisphosphonic Acid Partial Esters and Amides', *Phosphorus, Sulfur, and Silicon and the Related Elements*, 76: 1, 159 – 162

To link to this Article: DOI: 10.1080/10426509308032383

URL: <http://dx.doi.org/10.1080/10426509308032383>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

BISPHOSPHONATES. VI. METHYLENEBISPHOSPHONIC ACID PARTIAL ESTERS AND AMIDES

E. POHJALA^{a1}, H. NUPPONEN^{a1}, J. VEPSÄLÄINEN^b,
 H. NIKANDER^{a2} AND M-L. HEIKKILÄ-HOIKKA^{a2}

^aLeiras Oy, ¹P.O.Box 33, SF-33721 Tampere, ²P.O.Box 415, SF-20101, Turku, Finland. ^bUniversity of Kuopio, P.O.Box 1627, SF-70211 Kuopio, Finland

Abstract Syntheses and properties of various partial esters and amides 2-5 of some established methylenebisphosphonic acids 1 have been examined.

INTRODUCTION

Methylenebisphosphonates (MBP), characterized by a stabile P-C-P moiety (Table 1), are synthetic analogues of natural pyrophosphate. MBP tetraacids 1 (MBPA) bind strongly to hydroxyapatite (HA) and inhibit effectively the formation and dissolution of crystals of HA. Up to 50 % of a given dose of MBPA is taken up by the skeleton. The rest is excreted within hours in the urine. The half-life in bone is very long, one year or more.¹

TABLE 1 MBPA and partial derivatives

MBPA	Q ¹	Q ²	Structures	Type	≠ OH, - OH
A Clodronate	Cl	Cl		1	- Z ¹⁻⁴
B Etidronate	OH	CH ₃		2 Mono	Z ¹ Z ²⁻⁴
C Tiludronate	H	4-ClPhS		3 Asym.Di	Z ^{1,2} Z ^{3,4}
D Pamidronate	OH	(CH ₂) ₂ NH ₂		4 Sym Di	Z ^{1,3} Z ^{2,4}
E Alendronate	OH	(CH ₂) ₃ NH ₂		5 Tri	Z ¹⁻³ Z ⁴
F Risedronate	OH	3-PyCH ₂		6 Tetra	Z ¹⁻⁴

Zⁿ = NRR' or OR; R,R' = H, C_nH_m

MBPA inhibit the osteoclastic bone resorption via physicochemical interaction with bone mineral and via biochemical effects on cellular metabolism. Their properties

vary greatly from one MBPA to another. No clear structure-activity correlation has been found. Known MBPA (1) bind merely too tightly to bone. Some of them block mineralization causing dose-dependent side-effects. As very polar compounds they also suffer from a low bioavailability. Many MBPA are well tolerated with relatively few adverse events, specific for each. The clinical conditions of malignancy treated with MBPA include, e.g. osteolytic bone metastases, hypercalcemia, Paget's disease and ectopic calcification. MBPA are further investigated for benign diseases, especially osteoporosis and arthritis. In general they reduce the pain, lesions and fractures associated and improve the quality of life of patients.¹

RESULTS AND DISCUSSION

The P-C-P backbone of MBP allows variations either by changing the two groups (Q^1 and Q^2) on the central carbon and/or those (Z^1 , Z^2 , Z^3 and Z^4) on two phosphorus atoms. According to the literature about 3000 MBP have so far been reported. A part of them have been biologically tested. Nearly all are MBPA carrying different groups Q while only few partial derivatives (2-5) ($Z \neq OH$) of MBPA are known.

SCHEME Stepwise cleavage of tetraesters of **A**




TABLE 2 Partial derivatives of MBPA

	Z ¹	Z ²	Z ³	Z ⁴	Yield ^a	³¹ P NMR		
<hr/>								
A	<u>Clodronate</u>	Esters			%	δ (ppm)	² J _{PP} (Hz)	
<hr/>								
2a	OH ₂ B ¹	ONa	ONa	OMe	55	12.95	9.17	15.1
2b	ONa	ONa	ONa	OiPr	80	10.95	9.54	16.6
3a	ONa	ONa	OEt	OEt	41	16.27	7.20	16.0
3b	ONa	ONa	OH _{ex}	OH _{ex}	95	11.01	6.48	14.7
4a	OH ₂ B ¹	OMe	OH ₂ B ¹	OMe	95	9.70		
4b	OH ₂ B ²	OEt	OH ₂ B ²	OMe	84	10.03	8.74	15.5
4c	ONa	OEt	ONa	OEt	81	9.20		
4d	OH ₂ B ³	OiPr	OH ₂ B ³	OiPr	83	7.86		
5a	ONa	OMe	OMe	OMe	≈90	16.46	3.42	19.6
5b	ONMeBu ₃	OMe	OMe	OMe	≈100	15.50	4.25	16.6
5c	ONa	OEt	OEt	OEt	≈80	13.47	5.58	17.0
5d	OMePy	OMe	OiPr	OiPr	≈80	11.12	4.85	17.3
<hr/>								
A'	<u>Clodronate</u>	Amides			%	δ (ppm)	² J _{PP} (Hz)	
<hr/>								
2a	ONa	ONa	ONa	NHBu	≈80	9.49	7.11	21.0
2b	ONa	ONa	ONa	NEt ₂	86	15.72	10.23	15.2
3a	OH	OH	B ³	OEt	68	13.39	8.29	22.6
3b	ONa	ONa	NEt ₂	NEt ₂	63	32.16	8.60	15.6
4a	OH ₂ B ³	OMe	OH ₂ B ³	B ³	97	9.70	0.82	15.4
5a	ONMeBu ₃	OMe	NMeBn	OEt	≈100	18.77	4.94	17.9
5b	ONMeBu ₃	OMe	NEt ₂	NEt ₂	98	27.88	6.17	17.2
5c	OH ₂ B ¹	NEt ₂	NEt ₂	NEt ₂	85	30.19	12.26	16.5
<hr/>								
B ¹ = Piperidine, B ² = 4-Me-Piperazine, B ³ = Morpholine								
<hr/>								
B	<u>Etidronate</u>	Esters			%	δ (ppm)	² J _{PP} (Hz)	
<hr/>								
2a	ONa	ONa	ONa	OMe	^b	24.86	17.25	27.3
2b	OH	OH	OH	OiPr	^b	22.76	17.72	27.1
3a	ONa	ONa	OiPr	OiPr	^b	23.24	16.80	37.6
4a	ONa	OMe	ONa	OMe	72	21.19		
5a	ONa	OMe	OMe	OMe	^b	28.41	16.89	34.8
<hr/>								
C	<u>Tiludronate</u>	Esters			%	δ (ppm)	² J _{PP} (Hz)	
<hr/>								
2a	ONa	ONa	ONa	OiPr	^b	18.25	12.21	9.8
3a	OH	OH	OiPr	OiPr	^b	22.79	10.84	15.2
4a	OH	OiPr	OH	OiPr	^b	14.00		

^aIsolated, or from ³¹P NMR spectra. Based on **6**^bSeveral chromatographic or crystallization steps

Compounds

In order to explore the biological properties of some new partial derivatives of MPBA the esters and amides **2-5** with desired better absorption and controlled affinity for bone with preserved resorption inhibition were prepared. Thus the selective cleavage of tetraesters, -amides and -amide esters **6** their P-C-P backbone being constructed from suitable monophosphonic parts gave, e.g. partial esters (**A2-A5**) of clodronate (**A**) as depicted in Scheme. Reactions from tetraacid **A1** or -acid chloride and further transformations of **A2-A5** were also exploited. Partial amides and amide esters (**A'2-A'5**) of **A** were analogously obtained.

Other partial alkyl esters **2-5** synthesized in this study were those of other MBPA already clinically applied (**B, D**) or in advanced research phase (**C, E, F**), as well as partial esters of a series of MBPA with related Q^1 and Q^2 . Representative structures, yields and ^{31}P NMR data for partial derivatives of **A, A', B** and **C** are shown (Table 2).

Properties

Hydrolytic cleavage aptitudes of tetra compounds **6** and each subsequent partial derivative (**2-5**) were surprisingly greatly depending on differences in substituents Q and Z , the best method for each group and combination varying.

Phosphorus-31 NMR at 101 MHz provided a powerful means to follow the progress of reactions and to check the final purity of the products. The structures, substitution pattern and nature were obtained from coupled spectra.

Mono derivatives **2** complex still with calcium but this being reduced towards the higher derivatives (**3-5**). Binding to HA and inhibition of precipitation were not essential to resorption inhibition in vitro or in vivo.

REFERENCES

1. H. Fleisch, *Drugs*, **42**, 919 (1991)
2. Doctoral Thesis of J.V. (1992)